Ballicules.com

Velpatasvir

in EPCLUSA

What it isHCV NS5A inhibitor, given with sofosbuvir; chronic hepatitis C.

Why this onePangenotypic, so genotyping is unnecessary, with cure rates above 95%.

What limits itHepatitis B reactivation, so B status must be known first. Amiodarone with sofosbuvir causes severe bradycardia; acid suppressants reduce absorption.

FDA-approved for

FDA label

BOXED WARNING Risk of hepatitis B virus reactivation in HCV/HBV coinfected patients (some cases fulminant hepatitis, hepatic failure, death). Test all patients for HBV before treatment.
FDA dosingPopulationStartTargetMax
Chronic HCV genotype 1–6, no cirrhosis or compensated cirrhosis (Child-Pugh A)Adults & peds ≥6 y or ≥17 kgEPCLUSA (sofosbuvir 400 mg / velpatasvir 100 mg) QD ×12 weeks1 tablet QD ×12 weeks
Chronic HCV, decompensated cirrhosis (Child-Pugh B or C)AdultsEPCLUSA + ribavirin QD ×12 weeks1 tablet QD + ribavirin ×12 weeks
Chronic HCV genotype 1–6Peds ≥6 y or ≥17 kgWeight-based (per label Table 2) QD ×12 weeksWeight-based QD

Renal No dosage adjustment needed, including ESRD on dialysis.

Hepatic Decompensated cirrhosis (Child-Pugh B/C): add ribavirin.

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy With ribavirin: contraindicated in pregnancy; EPCLUSA alone — no adequate human data.

Lactation Unknown whether present in human milk.

⚠ BOXED WARNING

Principal riskHepatitis B reactivation; amiodarone causes severe bradycardia

Classes and tags

Clinical profile

Direct muscarinic antagonism0 / 4

Mechanism of action: Velpatasvir ballicule

Velpatasvir ballicule: receptor binding, kinetics and half-life diagram

Open Velpatasvir in the interactive console ↗

Memory aids: mascots and interaction avatars

Velpatasvir BCRP inhibitor avatar
BCRP inhibitor

Open Velpatasvir in the interactive console ↗